T1	intervention 110 151	tailored dose-dense adjuvant chemotherapy
T2	age 741 752	18-65Â years
T3	eligibility 754 812	ECOG PS 0-1 with at least one positive axillary lymph node
T4	outcome-Measure 878 917	safety and feasibility of the treatment
T5	total-participants 1120 1123	124
T8	outcome 1205 1237	probability for 10-year survival
T9	control 707 718	TAC regimen
T10	iv-bin-percent 1242 1246	78.5
T11	iv-bin-percent 1248 1252	75.1
T12	cv-bin-percent 1258 1263	63.4%
T13	outcome 1272 1293	relapse free survival
T14	iv-bin-percent 1294 1298	64.1
T15	iv-bin-percent 1300 1304	71.0
T16	cv-bin-percent 1310 1315	59.5%
T7	outcome 1398 1440	cardiotoxicity or hematologic malignancies
T17	outcome 1457 1474	lost to follow-up
